High-risk neuroblastoma has a poor prognosis despite intense treatment, demonstrating the need for new therapeutic strategies. Here we evaluated the effects of rigosertib (ON-01910.Na) in preclinical models of high-risk neuroblastoma. Among several hundred cancer cell lines representing 24 tumor types, neuroblastoma was the most sensitive to rigosertib. Treatment of MYCN-amplified neuroblastoma organoids resulted in organoid disintegration, decreased cell viability, and increased apoptotic cell death. Neuroblastoma response to rigosertib involved G2M cell cycle arrest and decreased phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204). Rigosertib delayed tumor growth and prolonged survival of mice carrying neuroblastoma MYCN-amplified PDX tumors (median survival: 31 days, treated; 22 days, vehicle) accompanied with increased apoptosis in treated tumors. We further identified vincristine and rigosertib as a potential promising drug combination treatment. Our results show that rigosertib might be a useful therapeutic agent for MYCN-amplified neuroblastomas, especially in combination with existing agents.

Original languageEnglish
Article number101149
JournalTranslational Oncology
Issue number8
Publication statusPublished - 2021 Aug

Subject classification (UKÄ)

  • Cancer and Oncology

Free keywords

  • Neuroblastoma
  • ON-01910
  • ON-01910.Na
  • Patient-derived xenografts
  • Rigosertib


Dive into the research topics of 'Anti-tumor effects of rigosertib in high-risk neuroblastoma'. Together they form a unique fingerprint.

Cite this